Anti-inflammatory effects of linagliptin in hemodialysis patients with diabetes

Inflammation and glycemic control are important prognosis‐related factors for hemodialysis (HD) patients; moreover, inflammation affects insulin secretion. Here, we evaluated the anti‐inflammatory effects of monotherapy with linagliptin—a dipeptidase‐4 inhibitor—in HD patients with type 2 diabetes....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Hemodialysis international 2014-04, Vol.18 (2), p.433-442
Hauptverfasser:	Nakamura, Yuya, Tsuji, Mayumi, Hasegawa, Hitomi, Kimura, Kengo, Fujita, Kiichiro, Inoue, Michiyasu, Shimizu, Tatsuo, Gotoh, Hiromichi, Goto, Yoshikazu, Inagaki, Masahiro, Oguchi, Katsuji
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Anti-Inflammatory Agents - therapeutic use diabetes Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Dipeptidyl-Peptidase IV Inhibitors - therapeutic use Female GLP-1 hemodialysis Humans Hypoglycemic Agents - therapeutic use IL-6 Kidney Failure, Chronic - blood Kidney Failure, Chronic - therapy Linagliptin Male PGE2 Purines - therapeutic use Quinazolines - therapeutic use Renal Dialysis - methods
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!